FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1264-1269 October 21, 1999 Number 17 Next

	Full Text PDF Editorial by du Bois, R.M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

ABSTRACT

Background Patients with idiopathic pulmonary fibrosis have progressive scarring of the lung and usually die within four to five years after symptoms develop. Treatment with oral glucocorticoids is often ineffective. We conducted an open, randomized trial of treatment with a combination of interferon gamma-1b, which has antifibrotic properties, and an oral glucocorticoid.

Methods We studied 18 patients with idiopathic pulmonary fibrosis who had not had responses to glucocorticoids or other immunosuppressive agents. Nine patients were treated for 12 months with oral prednisolone alone (7.5 mg daily, which could be increased to 25 to 50 mg daily), and nine with a combination of 200 µg of interferon gamma-1b (given three times per week subcutaneously) and 7.5 mg of prednisolone (given once a day).

Results All the patients completed the study. Lung function deteriorated in all nine patients in the group given prednisolone alone: total lung capacity decreased from a mean (±SD) of 66±8 percent of the predicted value at base line to 62±6 percent at 12 months. In contrast, in the group receiving interferon gamma-1b plus prednisolone, total lung capacity increased (from 70±6 percent of the predicted value at base line to 79±12 percent at 12 months, P<0.001 for the difference between the groups). In the group that received interferon gamma-1b plus prednisolone, the partial pressure of arterial oxygen at rest increased from 65±9 mm Hg at base line to 76±8 mm Hg at 12 months, whereas in the group that received prednisolone alone it decreased from 65±6 to 62±4 mm Hg (P<0.001 for the difference in the change from base-line values between the two groups); on maximal exertion, the value increased from 55±6 to 65±8 mm Hg in the group that received combined treatment and decreased from 55±6 mm Hg to 52±5 mm Hg in the group given prednisolone alone (P<0.001). The side effects of interferon gamma-1b, such as fever, chills, and muscle pain, subsided within the first 9 to 12 weeks.

Conclusions In a preliminary study, 12 months of treatment with interferon gamma-1b plus prednisolone was associated with substantial improvements in the condition of patients with idiopathic pulmonary fibrosis who had had no response to glucocorticoids alone.

Source Information

From the Department of Internal Medicine IV, Division of Pulmonary Medicine, University of Vienna Medical School, Vienna, Austria.

Address reprint requests to Dr. Block at the University of Vienna Medical School, Wahringer Gurtel 18-10, A-1090 Vienna, Austria, or at lutz-henning.block{at}akh-wein.ac.at.

Full Text of this Article

Related Letters:

Interferon Gamma-1b for the Treatment of Idiopathic Pulmonary Fibrosis
King T. E., Ziesche R., Block L.-H., Bois R.M. d.
Extract | Full Text  
N Engl J Med 2000; 342:974-975, Mar 30, 2000. Correspondence

This article has been cited by other articles:

• Kim, R., Meyer, K. C. (2008). Review: Therapies for interstitial lung disease: past, present and future. Therapeutic Advances in Respiratory Disease 2: 319-338 [Abstract]  
• Wells, A U, Hirani, N, on behalf of the BTS Interstitial Lung Disease Gui, (2008). Interstitial lung disease guideline. Thorax 63: v1-v58 [Full Text]  
• Laurent, G. J., McAnulty, R. J., Hill, M., Chambers, R. (2008). Escape from the Matrix: Multiple Mechanisms for Fibroblast Activation in Pulmonary Fibrosis. Proc Am Thorac Soc 5: 311-315 [Abstract] [Full Text]  
• Schwartz, D. A. (2008). Genetic Analysis of Sporadic and Familial Interstitial Pneumonia. Proc Am Thorac Soc 5: 343-347 [Abstract] [Full Text]  
• Rogliani, P., Mura, M., Assunta Porretta, M., Saltini, C. (2008). Review: New perspectives in the treatment of idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease 2: 75-93 [Abstract]  
• Clement, A., Eber, E. (2008). Interstitial lung diseases in infants and children. Eur Respir J 31: 658-666 [Abstract] [Full Text]  
• Williams, T J, Wilson, J W (2008). Challenges in pulmonary fibrosis: 7 {middle dot} Novel therapies and lung transplantation. Thorax 63: 277-284 [Abstract] [Full Text]  
• Raymond, T., Schaller, M., Hogaboam, C. M., Lukacs, N. W., Rochford, R., Kunkel, S. L. (2007). Toll-like Receptors, Notch Ligands, and Cytokines Drive the Chronicity of Lung Inflammation. Proc Am Thorac Soc 4: 635-641 [Abstract] [Full Text]  
• Scotton, C. J., Chambers, R. C. (2007). Molecular Targets in Pulmonary Fibrosis: The Myofibroblast in Focus. Chest 132: 1311-1321 [Abstract] [Full Text]  
• Cooker, L. A., Peterson, D., Rambow, J., Riser, M. L., Riser, R. E., Najmabadi, F., Brigstock, D., Riser, B. L. (2007). TNF-{alpha}, but not IFN-{gamma}, regulates CCN2 (CTGF), collagen type I, and proliferation in mesangial cells: possible roles in the progression of renal fibrosis. Am. J. Physiol. Renal Physiol. 293: F157-F165 [Abstract] [Full Text]  
• Gunther, A., Enke, B., Markart, P., Hammerl, P., Morr, H., Behr, J., Stahler, G., Seeger, W., Grimminger, F., Leconte, I., Roux, S., Ghofrani, H-A. (2007). Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. Eur Respir J 29: 713-719 [Abstract] [Full Text]  
• Rudd, R. M, Prescott, R. J, Chalmers, J C, Johnston, I. D A, for the Fibrosing Alveolitis Subcommittee of the R, (2007). British Thoracic Society Study on cryptogenic fibrosing alveolitis: response to treatment and survival. Thorax 62: 62-66 [Abstract] [Full Text]  
• Raghu, G. (2006). Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches.. Eur Respir J 28: 463-465 [Full Text]  
• Antoniou, K. M., Nicholson, A. G., Dimadi, M., Malagari, K., Latsi, P., Rapti, A., Tzanakis, N., Trigidou, R., Polychronopoulos, V., Bouros, D. (2006). Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur Respir J 28: 496-504 [Abstract] [Full Text]  
• Lee, C. G., Kang, H.-R., Homer, R. J., Chupp, G., Elias, J. A. (2006). Transgenic Modeling of Transforming Growth Factor-{beta}1: Role of Apoptosis in Fibrosis and Alveolar Remodeling.. Proc Am Thorac Soc 3: 418-423 [Abstract] [Full Text]  
• Giannopoulou, M., Iszkula, S. C., Dai, C., Tan, X., Yang, J., Michalopoulos, G. K., Liu, Y. (2006). Distinctive role of Stat3 and Erk-1/2 activation in mediating interferon-{gamma} inhibition of TGF-beta1 action. Am. J. Physiol. Renal Physiol. 290: F1234-F1240 [Abstract] [Full Text]  
• Weinberger, S. E. (2006). Update in pulmonary medicine.. ANN INTERN MED 144: 358-363 [Full Text]  
• Frankel, S. K., Cosgrove, G. P., Cha, S.-I., Cool, C. D., Wynes, M. W., Edelman, B. L., Brown, K. K., Riches, D. W. H. (2006). TNF-{alpha} Sensitizes Normal and Fibrotic Human Lung Fibroblasts to Fas-Induced Apoptosis. Am. J. Respir. Cell Mol. Bio. 34: 293-304 [Abstract] [Full Text]  
• Martinez, F. J. (2006). Acute Exacerbations in Idiopathic Pulmonary Fibrosis. ANN INTERN MED 144: 218-219 [Full Text]  
• Walter, N., Collard, H. R., King, T. E. Jr. (2006). Current perspectives on the treatment of idiopathic pulmonary fibrosis.. Proc Am Thorac Soc 3: 330-338 [Abstract] [Full Text]  
• Ask, K., Martin, G. E. M., Kolb, M., Gauldie, J. (2006). Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls.. Proc Am Thorac Soc 3: 389-393 [Abstract] [Full Text]  
• Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., Nicholson, A. G., Verbeken, E. K., Verschakelen, J., Flower, C. D.R., Capron, F., Petruzzelli, S., De Vuyst, P., van den Bosch, J. M.M., Rodriguez-Becerra, E., Corvasce, G., Lankhorst, I., Sardina, M., Montanari, M., the IFIGENIA Study Group, (2005). High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis.. NEJM 353: 2229-2242 [Abstract] [Full Text]  
• Doran, P., Egan, J. J. (2005). Herpesviruses: a cofactor in the pathogenesis of idiopathic pulmonary fibrosis?. Am. J. Physiol. Lung Cell. Mol. Physiol. 289: L709-L710 [Full Text]  
• Walters, D. M., Antao-Menezes, A., Ingram, J. L., Rice, A. B., Nyska, A., Tani, Y., Kleeberger, S. R., Bonner, J. C. (2005). Susceptibility of Signal Transducer and Activator of Transcription-1-Deficient Mice to Pulmonary Fibrogenesis. Am. J. Pathol. 167: 1221-1229 [Abstract] [Full Text]  
• Mora, A. L., Woods, C. R., Garcia, A., Xu, J., Rojas, M., Speck, S. H., Roman, J., Brigham, K. L., Stecenko, A. A. (2005). Lung infection with {gamma}-herpesvirus induces progressive pulmonary fibrosis in Th2-biased mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 289: L711-L721 [Abstract] [Full Text]  
• Nathan, S. D. (2005). Therapeutic Intervention: Assessing the Role of the International Consensus Guidelines. Chest 128: 533S-539S [Abstract] [Full Text]  
• Bouros, D., Antoniou, K. M. (2005). Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J 26: 693-703 [Abstract] [Full Text]  
• Tiitto, L., Heiskanen, U., Bloigu, R., Paakko, P., Kinnula, V., Kaarteenaho-Wiik, R. (2005). Thoracoscopic Lung Biopsy Is a Safe Procedure in Diagnosing Usual Interstitial Pneumonia. Chest 128: 2375-2380 [Abstract] [Full Text]  
• Pacanowski, M. A, Amsden, G. W (2005). Interferon Gamma-1b in the Treatment of Idiopathic Pulmonary Fibrosis. The Annals of Pharmacotherapy 39: 1678-1686 [Abstract] [Full Text]  
• Bajwa, E. K., Ayas, N. T., Schulzer, M., Mak, E., Ryu, J. H., Malhotra, A. (2005). Interferon-{gamma}1b Therapy in Idiopathic Pulmonary Fibrosis: A Metaanalysis. Chest 128: 203-206 [Abstract] [Full Text]  
• Halkos, M. E., Gal, A. A., Kerendi, F., Miller, D. L., Miller, J. I. Jr (2005). Role of Thoracic Surgeons in the Diagnosis of Idiopathic Interstitial Lung Disease. Ann. Thorac. Surg. 79: 2172-2179 [Abstract] [Full Text]  
• Gharaee-Kermani, M., Hatano, K., Nozaki, Y., Phan, S. H. (2005). Gender-Based Differences in Bleomycin-Induced Pulmonary Fibrosis. Am. J. Pathol. 166: 1593-1606 [Abstract] [Full Text]  
• Willis, B. C., Liebler, J. M., Luby-Phelps, K., Nicholson, A. G., Crandall, E. D., du Bois, R. M., Borok, Z. (2005). Induction of Epithelial-Mesenchymal Transition in Alveolar Epithelial Cells by Transforming Growth Factor-{beta}1: Potential Role in Idiopathic Pulmonary Fibrosis. Am. J. Pathol. 166: 1321-1332 [Abstract] [Full Text]  
• Bonniaud, P., Margetts, P. J., Kolb, M., Schroeder, J. A., Kapoun, A. M., Damm, D., Murphy, A., Chakravarty, S., Dugar, S., Higgins, L., Protter, A. A., Gauldie, J. (2005). Progressive Transforming Growth Factor {beta}1-induced Lung Fibrosis Is Blocked by an Orally Active ALK5 Kinase Inhibitor. Am. J. Respir. Crit. Care Med. 171: 889-898 [Abstract] [Full Text]  
• Burdick, M. D., Murray, L. A., Keane, M. P., Xue, Y. Y., Zisman, D. A., Belperio, J. A., Strieter, R. M. (2005). CXCL11 Attenuates Bleomycin-induced Pulmonary Fibrosis via Inhibition of Vascular Remodeling. Am. J. Respir. Crit. Care Med. 171: 261-268 [Abstract] [Full Text]  
• King, T. E. Jr, Safrin, S., Starko, K. M., Brown, K. K., Noble, P. W., Raghu, G., Schwartz, D. A. (2005). Analyses of Efficacy End Points in a Controlled Trial of Interferon-{gamma}1b for Idiopathic Pulmonary Fibrosis. Chest 127: 171-177 [Abstract] [Full Text]  
• Aghanouri, R., Ghanei, M., Aslani, J., Keivani-Amine, H., Rastegar, F., Karkhane, A. (2004). Fibrogenic cytokine levels in bronchoalveolar lavage aspirates 15 years after exposure to sulfur mustard. Am. J. Physiol. Lung Cell. Mol. Physiol. 287: L1160-L1164 [Abstract] [Full Text]  
• Xu, Y., Wang, L., Buttice, G., Sengupta, P. K., Smith, B. D. (2004). Major Histocompatibility Class II Transactivator (CIITA) Mediates Repression of Collagen (COL1A2) Transcription by Interferon {gamma} (IFN-{gamma}). J. Biol. Chem. 279: 41319-41332 [Abstract] [Full Text]  
• Singh, J., Steele, M. (2004). Acute Respiratory Failure After a Single Dose of Interferon-gamma. Chest 126: 994S-995S [Abstract]  
• Nadrous, H. F., Ryu, J. H., Douglas, W. W., Decker, P. A., Olson, E. J. (2004). Impact of Angiotensin-Converting Enzyme Inhibitors and Statins on Survival in Idiopathic Pulmonary Fibrosis. Chest 126: 438-446 [Abstract] [Full Text]  
• Khalil, N., O'Connor, R. (2004). Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment. CMAJ 171: 153-160 [Abstract] [Full Text]  
• Dauber, J. H., Gibson, K. F., Kaminski, N. (2004). Interferon-{gamma} 1b in Idiopathic Pulmonary Fibrosis: What We Know and What Must We Learn. Am. J. Respir. Crit. Care Med. 170: 107-108 [Full Text]  
• Strieter, R. M., Starko, K. M., Enelow, R. I., Noth, I., Valentine, V. G., the other members of the Idiopathic Pulmonary Fibr, (2004). Effects of Interferon-{gamma} 1b on Biomarker Expression in Patients with Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 170: 133-140 [Abstract] [Full Text]  
• Inoue, T., Fujishima, S., Ikeda, E., Yoshie, O., Tsukamoto, N., Aiso, S., Aikawa, N., Kubo, A., Matsushima, K., Yamaguchi, K. (2004). CCL22 and CCL17 in rat radiation pneumonitis and in human idiopathic pulmonary fibrosis. Eur Respir J 24: 49-56 [Abstract] [Full Text]  
• Collard, H. R., Ryu, J. H., Douglas, W. W., Schwarz, M. I., Curran-Everett, D., King, T. E. Jr., Brown, K. K. (2004). Combined Corticosteroid and Cyclophosphamide Therapy Does Not Alter Survival in Idiopathic Pulmonary Fibrosis. Chest 125: 2169-2174 [Abstract] [Full Text]  
• Wen, F.-Q., Liu, X., Kobayashi, T., Abe, S., Fang, Q., Kohyama, T., Ertl, R., Terasaki, Y., Manouilova, L., Rennard, S. I. (2004). Interferon-{gamma} Inhibits Transforming Growth Factor-{beta} Production in Human Airway Epithelial Cells by Targeting Smads. Am. J. Respir. Cell Mol. Bio. 30: 816-822 [Abstract] [Full Text]  
• Jakubzick, C., Choi, E. S., Carpenter, K. J., Kunkel, S. L., Evanoff, H., Martinez, F. J., Flaherty, K. R., Toews, G. B., Colby, T. V., Travis, W. D., Joshi, B. H., Puri, R. K., Hogaboam, C. M. (2004). Human Pulmonary Fibroblasts Exhibit Altered Interleukin-4 and Interleukin-13 Receptor Subunit Expression in Idiopathic Interstitial Pneumonia. Am. J. Pathol. 164: 1989-2001 [Abstract] [Full Text]  
• Jakubzick, C, Choi, E S, Kunkel, S L, Evanoff, H, Martinez, F J, Puri, R K, Flaherty, K R, Toews, G B, Colby, T V, Kazerooni, E A, Gross, B H, Travis, W D, Hogaboam, C M (2004). Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia. J. Clin. Pathol. 57: 477-486 [Abstract] [Full Text]  
• Evans, S. E., Colby, T. V., Ryu, J. H., Limper, A. H. (2004). Transforming Growth Factor-{beta}1 and Extracellular Matrix-Associated Fibronectin Expression in Pulmonary Lymphangioleiomyomatosis. Chest 125: 1063-1070 [Abstract] [Full Text]  
• Carvalho, C. R. R., Kairalla, R. A., Schettino, G. P. P., Crestani, B., Valeyre, D. (2004). Acute Respiratory Failure after Interferon-{gamma} Therapy in IPF. Am. J. Respir. Crit. Care Med. 169: 543-544 [Full Text]  
• Bartram, U., Speer, C. P. (2004). The Role of Transforming Growth Factor {beta} in Lung Development and Disease. Chest 125: 754-765 [Abstract] [Full Text]  
• Kaufman, J., Sime, P. J., Phipps, R. P. (2004). Expression of CD154 (CD40 Ligand) by Human Lung Fibroblasts: Differential Regulation by IFN-{gamma} and IL-13, and Implications for Fibrosis. J. Immunol. 172: 1862-1871 [Abstract] [Full Text]  
• Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., King, T. E. Jr., the Idiopathic Pulmonary Fibrosis Study Group, (2004). A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis. NEJM 350: 125-133 [Abstract] [Full Text]  
• Teirstein, A. S. (2004). The Elusive Goal of Therapy for Usual Interstitial Pneumonia. NEJM 350: 181-183 [Full Text]  
• Santiago, B., Galindo, M., Palao, G., Pablos, J. L. (2004). Intracellular Regulation of Fas-Induced Apoptosis in Human Fibroblasts by Extracellular Factors and Cycloheximide. J. Immunol. 172: 560-566 [Abstract] [Full Text]  
• Costabel, U. (2003). Idiopathic pulmonary fibrosis: a treatable disease?. Eur Respir J 22: 872-873 [Full Text]  
• Prasse, A., Muller, K-M., Kurz, C., Hamm, H., Virchow, J.C. Jr (2003). Does interferon-{gamma} improve pulmonary function in idiopathic pulmonary fibrosis?. Eur Respir J 22: 906-911 [Abstract] [Full Text]  
• Gunther, A., Lubke, N., Ermert, M., Schermuly, R. T., Weissmann, N., Breithecker, A., Markart, P., Ruppert, C., Quanz, K., Ermert, L., Grimminger, F., Seeger, W. (2003). Prevention of Bleomycin-induced Lung Fibrosis by Aerosolization of Heparin or Urokinase in Rabbits. Am. J. Respir. Crit. Care Med. 168: 1358-1365 [Abstract] [Full Text]  
• Segel, M. J., Izbicki, G., Cohen, P. Y., Or, R., Christensen, T. G., Wallach-Dayan, S. B., Breuer, R. (2003). Role of interferon-{gamma} in the evolution of murine bleomycin lung fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 285: L1255-L1262 [Abstract] [Full Text]  
• Kamp, D. W. (2003). Idiopathic Pulmonary Fibrosis: The Inflammation Hypothesis Revisited. Chest 124: 1187-1190 [Full Text]  
• Tajima, S., Oshikawa, K., Tominaga, S.-i., Sugiyama, Y. (2003). The Increase in Serum Soluble ST2 Protein Upon Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Chest 124: 1206-1214 [Abstract] [Full Text]  
• Wynes, M. W., Riches, D. W. H. (2003). Induction of Macrophage Insulin-Like Growth Factor-I Expression by the Th2 Cytokines IL-4 and IL-13. J. Immunol. 171: 3550-3559 [Abstract] [Full Text]  
• Kaminski, N., Belperio, J. A., Bitterman, P. B., Chen, L., Chensue, S. W., Choi, A. M.K., Dacic, S., Dauber, J. H., du Bois, R. M., Enghild, J. J., Fattman, C. L., Grutters, J. C., Haegens, A., Hanford, L. E., Heintz, N., Henson, P. M., Hogaboam, C., Kagan, V. E., Keane, M. P., Kunkel, S. L., Land, S., Loyd, J. E., Lukacs, N., MacPherson, M., Manning, B., Manning, N., Martinelli, M., Moller, D. R., Morse, D., Mossman, B., Noble, P. W., Nowak, N., Oury, T. D., Pardo, A., Perez, A., Petty, T. L., Phan, S. H., Ramos-Nino, M. E., Ray, P., Rogers, R. M., Sato, H., Scapoli, L., Schaefer, L. M., Selman, M., Stern, M., Strollo, D. C., Tyurin, V. A., Valnickova, Z., Welsh, K. I., Witzmann, F. A., Yousem, S. A., Strieter, R. M. (2003). Idiopathic Pulmonary Fibrosis. Am. J. Respir. Cell Mol. Bio. 29: S1-105 [Full Text]  
• Olman, M. A., Matthay, M. A. (2003). Transforming growth factor-{beta} induces fibrosis in immune cell-depleted lungs. Am. J. Physiol. Lung Cell. Mol. Physiol. 285: L522-L526 [Full Text]  
• Wittram, C., Mark, E. J., McLoud, T. C. (2003). CT-Histologic Correlation of the ATS/ERS 2002 Classification of Idiopathic Interstitial Pneumonias. RadioGraphics 23: 1057-1071 [Abstract] [Full Text]  
• Xaubet, A., Marin-Arguedas, A., Lario, S., Ancochea, J., Morell, F., Ruiz-Manzano, J., Rodriguez-Becerra, E., Rodriguez-Arias, J. M., Inigo, P., Sanz, S., Campistol, J. M., Mullol, J., Picado, C. (2003). Transforming Growth Factor-{beta}1 Gene Polymorphisms Are Associated with Disease Progression in Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 168: 431-435 [Abstract] [Full Text]  
• Bergeron, A., Soler, P., Kambouchner, M., Loiseau, P., Milleron, B., Valeyre, D., Hance, A.J., Tazi, A. (2003). Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-{beta} and IL-10. Eur Respir J 22: 69-76 [Abstract] [Full Text]  
• Silver, R. F., Zukowski, L., Kotake, S., Li, Q., Pozuelo, F., Krywiak, A., Larkin, R. (2003). Recruitment of Antigen-Specific Th1-Like Responses to the Human Lung following Bronchoscopic Segmental Challenge with Purified Protein Derivative of Mycobacterium tuberculosis. Am. J. Respir. Cell Mol. Bio. 29: 117-123 [Abstract] [Full Text]  
• Chilosi, M., Poletti, V., Zamo, A., Lestani, M., Montagna, L., Piccoli, P., Pedron, S., Bertaso, M., Scarpa, A., Murer, B., Cancellieri, A., Maestro, R., Semenzato, G., Doglioni, C. (2003). Aberrant Wnt/{beta}-Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis. Am. J. Pathol. 162: 1495-1502 [Abstract] [Full Text]  
• Selman, M. (2003). A Dark Side of Interferon-{gamma} in the Treatment of Idiopathic Pulmonary Fibrosis?. Am. J. Respir. Crit. Care Med. 167: 945-946 [Full Text]  
• Honore, I., Nunes, H., Groussard, O., Kambouchner, M., Chambellan, A., Aubier, M., Valeyre, D., Crestani, B. (2003). Acute Respiratory Failure after Interferon-{gamma} Therapy of End-Stage Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 167: 953-957 [Abstract] [Full Text]  
• Collard, H. R., King, T. E. Jr (2003). Demystifying Idiopathic Interstitial Pneumonia. Arch Intern Med 163: 17-29 [Abstract] [Full Text]  
• Antoniou, K. M., Ferdoutsis, E., Bouros, D. (2003). Interferons and Their Application in the Diseases of the Lung. Chest 123: 209-216 [Abstract] [Full Text]  
• Strieter, R. M., Belperio, J. A., Keane, M. P. (2002). CXC Chemokines in Angiogenesis Related to Pulmonary Fibrosis. Chest 122: 298S-301S [Abstract] [Full Text]  
• Belperio, J. A., Dy, M., Burdick, M. D., Xue, Y. Y., Li, K., Elias, J. A., Keane, M. P. (2002). Interaction of IL-13 and C10 in the Pathogenesis of Bleomycin-Induced Pulmonary Fibrosis. Am. J. Respir. Cell Mol. Bio. 27: 419-427 [Abstract] [Full Text]  
• Venkatesan, N., Roughley, P. J., Ludwig, M. S. (2002). Proteoglycan expression in bleomycin lung fibroblasts: role of transforming growth factor-beta 1 and interferon-gamma. Am. J. Physiol. Lung Cell. Mol. Physiol. 283: L806-L814 [Abstract] [Full Text]  
• Selman, M. (2002). From Anti-inflammatory Drugs Through Antifibrotic Agents to Lung Transplantation : A Long Road of Research, Clinical Attempts, and Failures in the Treatment of Idiopathic Pulmonary Fibrosis. Chest 122: 759-761 [Full Text]  
• Vicencio, A. G., Eickelberg, O., Stankewich, M. C., Kashgarian, M., Haddad, G. G. (2002). Regulation of TGF-beta ligand and receptor expression in neonatal rat lungs exposed to chronic hypoxia. J. Appl. Physiol. 93: 1123-1130 [Abstract] [Full Text]  
• Matsuoka, H., Arai, T., Mori, M., Goya, S., Kida, H., Morishita, H., Fujiwara, H., Tachibana, I., Osaki, T., Hayashi, S. (2002). A p38 MAPK inhibitor, FR-167653, ameliorates murine bleomycin-induced pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 283: L103-L112 [Abstract] [Full Text]  
• Wahidi, M. M., Ravenel, J., Palmer, S. M., McAdams, H. P. (2002). Progression of Idiopathic Pulmonary Fibrosis in Native Lungs After Single Lung Transplantation*. Chest 121: 2072-2076 [Abstract] [Full Text]  
• Hubbard, R., Venn, A. (2002). The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford) 41: 676-679 [Abstract] [Full Text]  
• RUDIGER, J. J., ROTH, M., BIHL, M. P., CORNELIUS, B. C., JOHNSON, M., ZIESCHE, R., BLOCK, L.-H. (2002). Interaction of C/EBP{alpha} and the glucocorticoid receptor in vivo and in nontransformed human cells. FASEB J. 16: 177-184 [Abstract] [Full Text]  
• WANG, H.-D., YAMAYA, M., OKINAGA, S., JIA, Y.-X., KAMANAKA, M., TAKAHASHI, H., GUO, L.-Y., OHRUI, T., SASAKI, H. (2002). Bilirubin Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats. Am. J. Respir. Crit. Care Med. 165: 406-411 [Abstract] [Full Text]  
• PETERS-GOLDEN, M., BAILIE, M., MARSHALL, T., WILKE, C., PHAN, S. H., TOEWS, G. B., MOORE, B. B. (2002). Protection from Pulmonary Fibrosis in Leukotriene-Deficient Mice. Am. J. Respir. Crit. Care Med. 165: 229-235 [Abstract] [Full Text]  
• (2002). American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias . This Joint Statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors, June 2001 and by The ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 165: 277-304 [Full Text]  
• Lee, C. G., Homer, R. J., Zhu, Z., Lanone, S., Wang, X., Koteliansky, V., Shipley, J. M., Gotwals, P., Noble, P., Chen, Q., Senior, R. M., Elias, J. A. (2001). Interleukin-13 Induces Tissue Fibrosis by Selectively Stimulating and Activating Transforming Growth Factor {beta}1. J. Exp. Med. 194: 809-822 [Abstract] [Full Text]  
• Gross, T. J., Hunninghake, G. W. (2001). Idiopathic Pulmonary Fibrosis. NEJM 345: 517-525 [Full Text]  
• Katzenstein, A.-L. A., Myers, J. L. (2001). Idiopathic Pulmonary Fibrosis . To Biopsy or Not to Biopsy. Am. J. Respir. Crit. Care Med. 164: 185-186 [Full Text]  
• Selman, M. (2001). Idiopathic Pulmonary Fibrosis Challenges for the Future. Chest 120: 8-10 [Full Text]  
• Stern, J.-B., Mal, H., Groussard, O., Brugiere, O., Marceau, A., Jebrak, G., Fournier, M. (2001). Prognosis of Patients With Advanced Idiopathic Pulmonary Fibrosis Requiring Mechanical Ventilation for Acute Respiratory Failure. Chest 120: 213-219 [Abstract] [Full Text]  
• Keane, M. P., Belperio, J. A., Burdick, M. D., Strieter, R. M. (2001). IL-12 attenuates bleomycin-induced pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 281: L92-L97 [Abstract] [Full Text]  
• du Bois, R.M., Wells, A.U. (2001). Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis. Eur Respir J 18: 43S-55s [Abstract] [Full Text]  
• Strieter, R. M. (2001). Mechanisms of Pulmonary Fibrosis : Conference Summary. Chest 120: 77S-85S [Full Text]  
• Blom, I E, van Dijk, A J, de Weger, R A, Tilanus, M G J, Goldschmeding, R (2001). Identification of human ccn2 (connective tissue growth factor) promoter polymorphisms. Mol. Pathol. 54: 192-196 [Abstract] [Full Text]  
• Maeyama, T., Kuwano, K., Kawasaki, M., Kunitake, R., Hagimoto, N., Hara, N. (2001). Attenuation of bleomycin-induced pneumopathy in mice by monoclonal antibody to interleukin-12. Am. J. Physiol. Lung Cell. Mol. Physiol. 280: L1128-L1137 [Abstract] [Full Text]  
• Chen, E. S., Greenlee, B. M., Wills-Karp, M., Moller, D. R. (2001). Attenuation of Lung Inflammation and Fibrosis in Interferon-{gamma}-Deficient Mice after Intratracheal Bleomycin. Am. J. Respir. Cell Mol. Bio. 24: 545-555 [Abstract] [Full Text]  
• EICKELBERG, O., PANSKY, A., KOEHLER, E., BIHL, M., TAMM, M., HILDEBRAND, P., PERRUCHOUD, A. P., KASHGARIAN, M., ROTH, M. (2001). Molecular mechanisms of TGF-{beta} antagonism by interferon {gamma} and cyclosporine A in lung fibroblasts. FASEB J. 15: 797-806 [Abstract] [Full Text]  
• Krishna, G., Liu, K., Shigemitsu, H., Gao, M., Raffin, T. A., Rosen, G. D. (2001). PG490-88, a Derivative of Triptolide, Blocks Bleomycin-Induced Lung Fibrosis. Am. J. Pathol. 158: 997-1004 [Abstract] [Full Text]  
• Selman, M., King, T. E. Jr., Pardo, A. (2001). Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy. ANN INTERN MED 134: 136-151 [Abstract] [Full Text]